September 2026Investor PresentationDeveloping new therapies to treat kidney diseases with unmet clinical needsAuthorised for lodgement by the Board of the Company2Forward looking statementsThis presentation includes forward-looking statements that are subject to risks and uncertainties. Although we...
Dimerix Investor Presentation
Filed with ASX · · 35 pages · English
Release
In the deck
Earlier from Dimerix
- S&P DJI Announces September 2026 Quarterly Rebalance
- Dimerix secures a$34 million non-dilutive facility to fund key clinical milestones
- Dimerix Secures A$34 Million Non-Dilutive Funding Facility
- Trading Halt
- Appendix 4E and 2026 Annual Report
Later from Dimerix
- Dimerix DMX-652 Granted Mexican Composition of Matter Patent
- Dimerix Presents at E&P Healthcare Conference 2026
- Waiver of Listing Rule 10.1 Granted
- Dimerix Presents at ASX SMIDcaps Conference 2026
- Dimerix Draws Down A$17M Under Non-Dilutive Funding Facility
Follow Dimerix into a list and get an email when it puts out news.
Follow Dimerix